Genomtec S.A.

Related Party Transaction • Jun 27, 2022

Signing a commercial agreement for distribution of Genomtec_#174; IDTheManagement Board of Genomtec S.A. (_quot;Issuer_quot;, _quot;Company_quot;) announces thattoday, i.e., 27 June 2022, it signed an agreement (the _quot;Agreement_quot;) withForLab SA, a distributor based in Belgium (_quot;Contractor_quot;) for the supplyof its flagship product Genomtec_#174; ID (_quot;Product_quot;). Under the Agreement,the minimum purchase values for the analyser and reaction cards will beestablished on a quarterly basis after the Contracting Party conducts anearly market adoption assessment for the Product. The Contracting Partywill have the right to exclusive distribution in Belgium, TheNetherlands and Luxembourg. At the same time, pursuant to the Agreement,the Contracting Party shall not undertake cooperation within the scopeof sale of other, similar devices on the territory of the abovementionedcountries. The remaining provisions of the Agreement do not differ fromtypical conditions for this type of transactions.The contractingParty is a trustworthy company specializing in the import anddistribution of diagnostics, medical devices, and life science reagentsfrom worldwide suppliers into Belgium, The Netherlands and Luxembourg.The company was founded in 1982 and is headquartered in Brussels. Itsells to customers based in laboratories of large teaching hospitals andsmaller healthcare facilities, universities, veterinary institutes,governmental laboratories, contract research organizations,pharmaceutical and biotech companies.The Management Board of theCompany considered the conclusion of the Agreement to be confidentialinformation, because the Contracting Party declared that after an earlymarket adoption assessment for the Product it would be ready to declarebinding purchase volumes, thus there are indications that the executionof the aforementioned Agreement may have a significant impact on theIssuer's future revenue situation, as well as on the popularisation ofthe Company's technology and Product.Therefore, in the opinion of theManagement Board, this information meets the criteria of confidentialinformation within the meaning of Article 17.1 MAR.